Acromegaly
1997: Research by Peter J. Kopchick and colleagues helped establish the potential of growth hormone receptor antagonism.
2000: Clinical development demonstrated that pegvisomant could effectively reduce circulating IGF-1 in patients with acromegaly.
2002: Approved by the US FDA for treatment of acromegaly.
Mechanism Of Action
Current Events
No comments:
Post a Comment